High density lipoprotein and it's dysfunction

Open Biochemistry Journal

Volumn 6, Issue , 2012, Pages 78-93

  Eren, Esin ^a   Yilmaz, Necat ^b   Aydin, Ozgur ^b  

^a Antalya Public Health Center of Ministry of Health   (Turkey)

^b Research Hospital of Ministry of Health   (Turkey)

Author keywords

HDL; HDL dysfunction; HDL functionality; HDL proteins; HDL subtypes; High density lipoprotein

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 3; CLUSTERIN; GLUTATHIONE PEROXIDASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SPHINGOSINE 1 PHOSPHATE; TORCETRAPIB; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; HEART PROTECTION; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ANALYSIS;

EID: 84865229811     PISSN: None     EISSN: 1874091X     Source Type: Journal    
DOI: 10.2174/1874091X01206010078     Document Type: Review

References (145)

1. Movva, I. R.; Rader, D. Laboratory Assessment of HDL Heteroge-neity and Function. Clin.Chem., 2008, 54,788-800.
2. Bruckert, E.; Hansel, B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int. J. Clin. Pract., 2007, 61,1905-1913.
3. Fogelman, A. M. The complexity of high-density lipoproteins. Circulation, 2010, 122, 1900-1991.
4. Shah, P. K. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship? Rev. Cardiovasc. Med., 2011, 12, 55-59.
5. Kones, R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug. Des. Devel. Ther., 2011, 5, 325-380.
6. Arsenault, B. J.; Lemieux, I.; Després, J. P.; Wareham N. J; Stroes E. S; Kastelein J. J; Khaw K. T; Boekholdt S. M. Comparison be-tween gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin. Chem., 2010, 56, 789-798.
7. Jahangiri, A. HDL and the acute phase response. Curr. Opin. Endocrinol. Diabetes Obes., 2010, 17, 156-160.
8. Camont, L.; Chapman, M. J.; Kontush, A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends. Mol. Med., 2011, 17, 594-603
9. Asztalos, B. F.; Tani, M.; Schaefer, E. J. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol., 2011, 22, 176-185.
10. Aviram, M.; Rosenblat, M.; Bisgaier, C. L.; Newton, R. S.; Primo-Parmo, S. L.; La Du, B. N. Paraoxonase inhibits high-density lipo-protein oxidation and preserves its functions. A possible peroxida-tive role for paraoxonase. J. Clin. Invest., 1998, 101,1581-1590.
11. Kontush, A.; Chapman, M. J. Why is HDL functionally deficient in type 2 diabetes? Curr. Diab. Rep., 2008, 8, 51-59.
12. Smith, J. D. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 151-155.
13. Superko, H. R. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation, 2009, 19, 2383-2395.
14. Hime, N. J.; Drew, K. J.; Wee, K.; Barter, P. J.; Rye, K. A. Forma-tion of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. J. Lipid. Res., 2006, 47, 15-22.
15. McGrowder, D.; Riley, C.; Morrison, E. Y.; Gordon, L. The role of high-density lipoproteins in reducing the risk of vascular dis-eases, neurogenerative disorders, and cancer. Cholesterol, 2011, 2011, 496925.
16. Lewis, G. F.; Rader, D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96, 1221-1232.
17. Groen, A. K.; Oude, Elferink, R. P; Verkade, H J., Kuipers, F. The ins and outs of reverse cholesterol transport. Ann. Med., 2004, 36,135-145.
18. Brewer, H. B. Jr.; Santamarina-Fojo, S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol., 2003, 91, 3-11.
19. Sato, K.; Okajima, F. Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein. World J. Biol. Chem., 2010, 1, 327-337.
20. Thomas, M. J.; Bhat, S.; Sorci-Thomas, M. G. Three-dimensional models of HDL apoA-I: implications for its assembly and function. Lipid. Res., 2008, 49,1875-1883.
21. Di Bartolo, B. A.; Nicholls, S. J.; Bao, S.; Rye, K. A.; Heather, A. K.; Barter, P. J.; Bursill, C. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis, 2011, 17, 395-400.
22. Navab, M.; Anantharamaiah, G. M.; Reddy, S. T.; Van Lenten, B. J.; Ansell, B. J.; Fogelman, A. M. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat. Clin. Pract. Endocri-nol. Metab., 2006, 2, 504-511.
23. Alexander, E. T.; Tanaka, M.; Kono, M.; Saito, H.; Rader, D. J.; Phillips, M. C. Structural and functional consequences of the Mi-lano mutation (R173C) in human apolipoprotein A-I. J. Lipid Res., 2009, 50,1409-1419.
24. Frank, P. G.; Marcel, Y. L. Apolipoprotein A-I: structure-function relationships. J. Lipid Res., 2000, 41, 853-872.
25. Sorci-Thomas, M. G.; Bhat, S.; Thomas, M. J. Activation of leci-thin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin. Lipidol., 2009, 4,113-124.
26. Koike, T.; Kitajima, S.; Yu, Y.; Li, Y.; Nishijima, K.; Liu, E.; Sun, H.; Waqar, A. B.; Shibata, N.; Inoue, T.; Wang, Y.; Zhang, B.; Kobayashi, J.; Morimoto, M.; Saku, K.; Watanabe, T.; Fan, J. Ex-pression of human apoAII in transgenic rabbits leads to dyslipide-mia: a new model for combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 204
27. Blanco-Vaca, F.; Escolà-Gil, J. C.; Martín-Campos, J. M.; Julve, J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res., 2001, 42,1727-1739.
28. Assmann, G.; Nofer, J. R. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med., 2003, 54, 321-341.
29. Van Eck, M.; Pennings, M.; Hoekstra, M.; Out, R.; Van Berkel, T. J. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr. Opin. Lipidol., 2005, 16, 307-315.
30. Julve, J.; Blanco-Vaca, F.; Escolà-Gil, J. C. On the mechanisms by which human apolipoprotein A-II gene variability relates to hyper-triglyceridemia. Circulation, 2002, 105, e129.
31. Gaidukov, L.; Viji, R. I.; Yacobson, S.; Rosenblat, M.; Aviram, M.; Tawfik, D. S. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry, 2010, 49,532-538.
32. Asztalos, B. F.; Schaefer, E. J.; Horvath, K. V.; Yamashita, S.; Miller, M.; Franceschini, G.; Calabresi, L. J. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. Lipid Res., 2007, 48, 592-599.
33. Hajjar, D. P.; Haberland, M. E. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J. Biol. Chem., 1997, 272, 22975-22978.
34. Podrez, E. A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol., 2010, 37, 719-725.
35. Besler, C., Heinrich, K., Riwanto, M., Lüscher, T.; F.; Landmesser, U. High-density lipoprotein-mediated anti-atherosclerotic and en-dothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr. Pharm. Des., 2010, 16, 1480-1493.
36. Ponnuswamy, P.; Schröttle, A.; Ostermeier, E.; Grüner, S.; Huang, P.; L.; Ertl, G.; Hoffmann, U.; Nieswandt, B.; Kuhlencordt, P. J. eNOS Protects from Atherosclerosis Despite Relevant Superoxide Production by the Enzyme in apoE. Mice, 2012, 7, 30193.
37. Cabana, V. G.; Reardon, C. A.; Feng, N.; Neath, S.; Lukens, J.; Getz, G. S. Serum paraoxonase: effect of the apolipoprotein com-position of HDL and the acute phase response. J. Lipid Res., 2003, 44, 780-792.
38. Kontush, A.; Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipi-demia, inflammation, and atherosclerosis. Pharmacol. Rev., 2006, 58, 342-374.
39. Scanu, A. M.; Edelstein, C. HDL: bridging past and present with a look at the future. FASEB J, 2008, 22, 4044-4054.
40. Kontush, A.; Chapman, M. J. High-density lipoproteins: structure, metabolism, function, and therapeutics. 1st ed., John Wiley & Sons, Inc: NJ, 2012.
41. Hortin, G. L.; Shen, R. F.; Martin, B. M.; Remaley, A. T. Diverse range of small peptides associated with high-density lipoprotein. Biochem. Biophys. Res. Commun., 2006, 340, 909-915.
42. Rezaee, F.; Casetta, B.; Levels, J. H.; Speijer, D.; Meijers, J. C. Proteomic analysis of high-density lipoprotein. Proteomics, 2006, 6, 721-730.
43. Huuskonen, J.; Olkkonen, V. M.; Jauhiainen, M.; Ehnholm, C. The impact of phospholipid transfer protein (PLTP) on HDLMetabo-lism. Atherosclerosis, 2001, 155, 269-281.
44. Lewis, G. F.; Rader D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96, 1221-1232.
45. Huuskonen, J.; Olkkonen, V. M.; Jauhiainen, M.; Ehnholm, C. The impact of phospholipid transfer protein (PLTP) on HDL metabo-lism. Atherosclerosis, 2001, 55, 269-281.
46. Yazdanyar, A.; Yeang, C. Jiang, X. C. Role of phospholipid trans-fer protein in high-density lipoprotein-mediated reverse cholesterol transport. Curr. Atheroscler. Rep., 2011, 13, 242-248.
47. Natarajan, P.; Ray, K. K.; Cannon, C. P. High-density lipoprotein and coronary heart disease current and future therapies. J. Am. Coll. Cardiol., 2010, 55, 1283-1299.
48. Ohashi, M. U.; Wang, X.; Yao, Q.; Chen, C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. Q. J. Med., 2005, 98, 845-856.
49. Lie, J.; Crom, R.; Gent, T.; Haperen, R.; Sadeghi-Niaraki, L.; Tol, A. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J. Lipid Res., 2004, 45, 805-811.
50. Ordovas, J. M.; Cupples, L. A.; Corella, D.; Otvos, J. D.; Osgood, D.; Martinez, A.; Lahoz, C.; Coltell, O.; Wilson, P. W.; Schaefer, E. J. Association of cholesteryl ester transfer protein-TaqIB poly-morphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1323-1329.
51. Gao, X.; Yuan, S.; Jayaraman, S.; Gursky, O. Differential stability of high-density lipoprotein subclasses: effects of particle size and protein composition. J. Mol. Biol., 2009, 387, 628-638.
52. Massey, J. B.; Pownall, H. J.; Macha, S.; Morris, J.; Tubb, M. R.; Silva, R. A. Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. J. Lipid Res., 2009, 50, 1229-1236.
53. Silva, R. A.; Huang, R.; Morris, J.; Fang, J.; Gracheva, E. O.; Ren, G.; Kontush, A.; Jerome, W. G.; Rye, K. A.; Davidson, W. S. Structure of apolipoprotein A-I in spherical high density lipopro-teins of different sizes. Proc. Natl. Acad. Sci. USA, 2008, 105, 12176-12181.
54. Jayaraman, S.; Gantz, D. L.; Gursky, O. Effects of protein oxida-tion on the structure and stability of model discoidal high-density lipoproteins. Biochemistry, 2008, 47, 3875-3882.
55. Duong, P. T.; Collins, H. L.; Nickel, M.; Lund-Katz, S.; Rothblat, G. H.; Phillips, M. C. Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I. J.Lipid Res., 2006, 47, 832-843.
56. Duong, P. T.; Weibel, G. L.; Lund-Katz, S.; Rothblat, G. H.; Phil-lips, M. C. Characterization and properties of pre beta-HDL parti-cles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J. Lipid. Res., 2008, 49, 1006-1014.
57. Wróblewska, M. The origin and metabolism of a nascent pre-β high density lipoprotein involved in cellular cholesterol efflux. Acta Biochim. Pol., 2011, 58, 275-285.
58. Rye, K. A.; Barter, P. J. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Bio-chim. Biophys. Acta, 2012, 1821, 473-480.
59. Kontush, A.; Chapman, M. J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 144-153.
60. Otvos, J. D.; Jeyarajah, E. J.; Bennett, D. W.; Krauss, R. M. Devel-opment of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and sub-species distributions from a single, rapid measurement. Clin. Chem., 1992, 38, 1632-1638.
61. Salonen, J. T.; Salonen, R.; Seppänen, K.; Rauramaa, R.; Tuomile-hto, J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation, 1991, 84, 129-139.
62. Hime, N. J.; Drew, K. J.; Wee, K.; Barter, P. J.; Rye, K. A. Forma-tion of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. J. Lipid Res., 2006, 47,115-122.
63. Rosenson, R. S.; Brewer, H. B. Jr.; Chapman, M. J.; Fazio, S.; Hussain, M. M.; Kontush, A.; Krauss, R. M.; Otvos, J. D.; Re-maley, A. T.; Schaefer, E. J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascu-lar events. Clin. Chem., 2011, 57, 392-410.
64. Gao, X.; Yuan, S.; Jayaraman, S.; Gursky, O. Differential stability of high-density lipoprotein subclasses: effects of particle size and protein composition. J. Mol. Biol., 2009, 387, 628-638.
65. O'Brien, T.; Nguyen, T. T.; Hallaway, B. J.; Hodge, D.; Bailey, K.; Holmes, D.; Kottke, B. A. The role of lipoprotein A-I and lipopro-tein A-I/A-II in predicting coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 228-231.
66. Duriez, P.; Fruchart, J. C. High-density lipoprotein subclasses and apolipoprotein A-I. Clin. Chim. Acta, 1999, 286, 97-114.
67. Barter, P. J.; Nicholls, S.; Rye, K. A.; Anantharamaiah, G. M.; Navab, M.; Fogelman, A. M. Antiinflammatory properties of HDL. Circ. Res., 2004, 95, 764-772.
68. Haas, M. J.; Mooradian, A. D. Inflammation, high-density lipopro-tein and cardiovascular dysfunction. Curr. Opin. Infect. Dis., 2011, 24, 265-272.
69. Kontush, A.; Chantepie, S.; Chapman, M. J. Small, dense HDL par-ticles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1881-1888.
70. Souza, J. A.; Vindis, C.; Hansel, B.; Nègre-Salvayre, A.; Therond, P.; Serrano, C. V. Jr.; Chantepie, S.; Salvayre, R.; Bruckert, E.; Chapman, M. J.; Kontush, A. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with de-fective anti-apoptotic activity. Atherosclerosis, 2008, 197(1), 84-94.
71. G. D.; Pirillo, A.; Ammirati, E.; Catapano, A. L. Emerging role of high density lipoproteins as a player in the im-mune system. Atherosclerosis, 2012, 220,11-21
72. Getz, G.S.; Wool, G.D.; Reardon, C.A. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other in-flammatory disorders. Curr. Pharm. Des., 2010, 16, 3173-3184.
73. Mackness, B.; Mackness, M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol., 2010, 660, 143-151.
74. Mineo, C.; Deguchi, H.; Griffin, J. H.; Shaul, P. W. Endothelial and antithrombotic actions of HDL. Circ. Res., 2000, 98, 1352-1364.
75. Sankaranarayanan, S.; Kellner-Weibel, G.; de la Llera-Moya, M.; Phillips, M. C.; Asztalos, B. F.; Bittman, R.; Rothblat, G. H. A sen-sitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J. Lipid Res., 2011, 52, 2332.
76. Nandi, S.; Ma, L.; Denis, M.; Karwatsky, J.; Li, Z.; Jiang, X. C.; Zha, X. ABCA1-mediated cholesterol efflux generates microparti-cles in addition to HDL through processes governed by membrane rigidity.J. Lipid Res., 2009, 50, 456-466.
77. Rader, D. J.; Alexander, E. T; Weibel, G. L.; Billheimer, J.; Rothblat, G. H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res., 2009, 50, 189-194.
78. Kapur, N. K.; Ashen, D.; Blumenthal, R. S. High density lipopro-tein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc. Health Risk Manag., 2008, 4, 39-57.
79. Rye, K. A.; Barter, P. J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 421-428.
80. Joy, T.; Hegele, R. A. The end of the road for CETP inhibitors after torcetrapib? Curr. Opin. Cardiol., 2009, 24(4), 24364-24371.
81. Nicholls, S. J. HDL: still a target for new therapies? Curr. Opin. Investig. Drugs, 2008, 9, 950-956.
82. Hegele, R A.; Joy, T. Is raising HDL a futile strategy for athero-protection? Nat. Rev. Drug Discov., 2008, 7,143-155.
83. Natarajan, P.; Ray, K. K.; Cannon, C. P. High-density lipoprotein and coronary heart disease: current and future therapies. J. Am. Coll. Cardiol., 2010, 55, 1283-1299.
84. Toth, P. P. Should we target HDL cholesterol level in lowering cardiovascular risk? Pol. Arch. Med. Wewn., 2009, 119, 667-672.
85. Smith, J. D. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb.Vasc. Biol., 2010, 30, 151-155.
86. Kellner-Weibel G.; de la Llera-Moya, M. Update on HDL recep-tors and cellular cholesterol transport. Curr. Atheroscler. Rep., 2011, 3, 233-241.
87. Fitzgerald, M. L.; Mujawar, Z.; Tamehiro, N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis, 2010, 211, 361-370.
88. von Eckardstein, A.; Nofer, J. R.; Assmann, G. High density lipo-proteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 13-27.
89. Zhang, W. Y.; Gaynor, P. M.; Kruth, H. S. Apolipoprotein E produced by human monocyte-derived macrophages mediates cho-lesterol efflux that occurs in the absence of added cholesterol ac-ceptors. J. Biol. Chem., 1996, 271, 28641-28646.
90. Larkin, L.; Khachigian, L. M.; Jessup, W. Regulation of apolipo-protein E production in macrophages. Int. J. Mol. Med., 2000, 6, 253-258.
91. Yin, K.; Liao, D. F.; Tang, C. K. ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol. Med., 2010, 16, 438-449.
92. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase, modified lipopro-teins, and atherogenesis. J. Lipid Res., 2009, 50, 346-351.
93. V. S.; Kakkar, V. V. Friend turns foe: transforma-tion of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol, 2011, 2011, 274629.
94. Camarota, L. M.; Woollett, L. A.; Howles, P. N. Reverse choles-terol transport is elevated in carboxyl ester lipase-knockout mice. FASEB J., 2011, 25, 1370-1377.
95. Julve, J.; Llaverias, G.; Blanco-Vaca, F.; Escolà-Gil, J. C. Seeking novel targets for improving in vivo macrophage-specific reverse cholesterol transport: translating basic science into new therapies for the prevention and treatment of atherosclerosis. Curr. Vasc. Pharmacol., 2011, 9, 220-237.
96. Ansell, B. J.; Watson, K. E.; Fogelman, A. M.; Navab, M.; Fon-arow, G. C. High-density lipoprotein function recent advances. J. Am. Coll. Cardiol., 2005, 46, 1792-1798.
97. Blache, D.; Gautier, T.; Tietge, U. J.; Lagrost, L. Activated plate-lets contribute to oxidized low-density lipoproteins and dysfunc-tional high-density lipoproteins through a phospholipase A2-dependent mechanism. FASEB J., 2012, 26, 927-937.
98. Nofer, J. R.; van Eck M. HDL scavenger receptor class B type I and platelet function. Curr. Opin. Lipid, 2011, 22, 277-282.
99. Mineo, C.; Deguchi, H.; Griffin, J. H.; Shaul, P. W.; Endothelial and antithrombotic actions of HDL. Circ. Res., 2006, 98, 1352-1364.
100. Li, D.; Weng, S.; Yang, B.; Zander, D. S.; Saldeen, T.; Nichols, W. W.; Khan, S.; Mehta, J. L. Inhibition of arterial thrombus for-mation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 378-383.
101. Griffin, J. H.; Kojima, K.; Banka, C. L.; Curtiss, L. K.; Fernández, J. A. High-density lipoprotein enhancement of anticoagulant activi-ties of plasma protein S and activated protein C. J. Clin. Invest., 1999, 103, 219-227.
102. Natorska, J.; Bykowska, K.; Hlawaty, M.; Marek, G.; Sadowski, J.; Undas, A. Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis. Heart, 2011, 97, 2023-2028.
103. Dart, A. M.; Chin-Dusting, J. P. Lipids and the endothelium. Cardiovasc. Res., 1999, 43, 308-322.
104. Yilmaz, N.; Aydin, O.; Yegin, A.; Tiltak, A.; Eren, E. Increased levels of total oxidant status and decreased activity of arylesterase in migraineurs. Clin. Biochem., 2011, 44, 832-837.
105. Bochkov, V. N.; Oskolkova, O. V.; Birukov, K. G.; Levonen, A. L.; Binder, C. J.; Stöckl, J. Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal, 2010, 12, 1009-1059.
106. Witting, P. K.; Song, C.; Hsu, K.; Hua, S.; Parry, S. N.; Aran, R.; Geczy, C.; Freedman, S. B. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic. Biol. Med., 2011, 51, 1390-1398.
107. Mineo, C.; Deguchi, H.; Griffin, J. H.; Shaul, P. W. Endothelial and antithrombotic actions of HDL. Circ. Res., 2006, 98, 1352-1364.
108. Kappelle, P. J.; Bijzet, J.; Hazenberg, B. P.; Dullaart, R. P. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch. Med. Res., 2011, 42, 219-225.
109. Shaul, P. W. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J.Physiol., 2003, 547, 21-33.
110. Uittenbogaard, A.; Shaul, P. W.; Yuhanna, I. S.; Blair, A.; Smart, E. J. High density lipoprotein prevents oxidized low density lipo-protein-induced inhibition of endothelial nitric-oxide synthase lo-calization and activation in caveolae. J. Biol. Chem., 2000, 275, 11278-11283.
111. King, V. L.; Thompson, J.; Tannock, L. R. Serum amyloid A in atherosclerosis. Curr. Opin. Lipidol., 2011, 22, 302-307.
112. Tang, C.; Liu, Y.; Kessler, P. S.; Vaughan, A. M.; Oram, J. F. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem., 2009, 284, 32336-32343.
113. Peng, D. Q.; Wu, Z.; Brubaker, G.; Zheng, L.; Settle, M.; Gross, E.; Kinter, M.; Hazen, S. L.; Smith, J. D. Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. Biol. Chem., 2005, 280, 33775-33784.
114. Yilmaz, N.; Aydin, O.; Yegin, A.; Tiltak, A.; Eren, E.; Aykal, G. Impaired oxidative balance and association of blood glucose; insu-lin and HOMA-IR index in migraine. Biochem. Med. (Zagreb), 2011, 21, 145-151.
115. Yilmaz, N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch. Med. Sci., 2012, 8, 1.
116. Yilmaz, N.; Eren, E.; Erel, O. Activity paraoxonase and aryles-terase and its relationship to antioxidat profiles in young basketball players and sedentary controls. Med. Sport, 2007, 11, 20-26.
117. Leopold, J. A. Loscalzo, J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic. Biol. Med., 2009, 47, 1673-1706.
118. La Du B. N. Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis? Arterioscler. Thromb. Vasc. Biol., 2001, 21, 467-468.
119. Tselepis, A. D.; Karabina, S. A.; Stengel, D.; Piédagnel, R.; Chap-man, M. J.; Ninio, E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J. Lipid Res., 2001, 42, 1645-1654.
120. Dennis, E. A.; Cao, J.; Hsu, Y. H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interven-tion. Chem. Rev., 2011, 111, 6130-6185.
121. Unno, N.; Nakamura, T.; Kaneko, H.; Uchiyama, T.; Yamamoto, N.; Sugatani, J.; Miwa M.; Nakamura, S. Plasma platelet-activating factor acetylhydrolase deficiency is associated with ath-erosclerotic occlusive disease in japan. J. Vasc. Surg., 2000, 32, 263-267.
122. Rodrigo, L.; Mackness, B.; Durrington, P. N.; Hernandez, A.; Mackness, M. I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J., 2001, 354, 1-7.
123. Goyal, J.; Wang, K.; Liu, M.; Subbaiah, P. V. J. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. Biol. Chem., 1997, 272, 16231-16239.
124. Degoma, E. M.; Rader, D. J. Novel HDL-directed pharmacothera-peutic strategies. Nat. Rev. Cardiol., 2011, 8, 266-277.
125. Sattler, K.; Levkau, B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Car-diovasc. Res., 2009, 82, 201-211
126. Karliner, J. S. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J. Cardiovasc. Pharmacol., 2009, 53, 189-197.
127. Ansell, B. J.; Watson, K. E.; Fogelman, A. M.; Navab, M.; Fon-arow, G. C. High-density lipoprotein function recent advances. J. Am. Coll. Cardiol., 2005, 46, 1792-1798.
128. Sharma, R. K.; Singh, V. N.; Reddy, H. K. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardio-vascular risk. Vasc. Health Risk Manag., 2009, 5, 793-799.
129. Paoletti, R.; Gotto, A. M. Jr.; Hajjar, D. P. Inflammation in athero-sclerosis and implications for therapy. Circulation, 2004, 109, 20-26.
130. Navab, M.; Ananthramaiah, G. M.; Reddy, S. T.; Van Lenten, B. J.; Ansell, B. J.; Hama, S.; Hough, G.; Bachini, E.; Grijalva, V. R.; Wagner, A. C.; Shaposhnik, Z.; Fogelman, A. M. The double jeop-ardy of HDL. Ann. Med., 2005, 37, 173-178.
131. Cheung, M. C.; Brown, B. G.; Marino Larsen, E. K.; Frutkin, A. D.; O'Brien, K. D.; Albers, J. J. Phospholipid transfer protein activ-ity is associated with inflammatory markers in patients with car-diovascular disease. Biochim. Biophys. Acta, 2006, 1762, 131-137.
132. Farbstein, D.; Blum, S.; Pollak, M.; Asaf, R.; Viener, H. L.; Lache, O.; Asleh, R.; Miller-Lotan, R.; Barkay, I.; Star, M.; Schwartz, A.; Kalet-Littman, S.; Ozeri, D.; Vaya, J.; Tavori, H.; Vardi, M.; Laor, A.; Bucher, S. E.; Anbinder, Y.; Moskovich, D.; Abbas, N.; Perry, N.; Levy, Y.; Levy, A. P. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis, 2011, 219, 240-244.
133. Ortiz-Muñoz, G.; Houard, X.; Martín-Ventura, J. L.; Ishida, B. Y.; Loyau, S.; Rossignol, P.; Moreno, J. A.; Kane, J. P.; Chalkley, R. J.; Burlingame, A. L.; Michel, J. B.; Meilhac, O. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antia-therogenic property. FASEB J., 2009, 23, 3129-3139.
134. Desrumaux, C.; Deckert, V.; Athias, A.; Masson, D.; Lizard, G.; Palleau, V.; Gambert, P.; Lagrost, L. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J., 1999, 13, 883-892.
135. Lucke, S.; Levkau, B. Endothelial functions of sphingosine-1-phosphate. Cell Physiol. Biochem., 2010, 26, 87-96.
136. Söderlund, S.; Soro-Paavonen, A.; Ehnholm, C.; Jauhiainen, M.; Taskinen, M. R. Hypertriglyceridemia is associated with prebeta-HDL concentrations in subjects with familial low HDL. J. Lipid Res., 2005, 46, 1643-1651.
137. Navab, M.; Reddy, S. T.; Van Lenten, B. J.; Fogelman, A. M. HDL and cardiovascular disease: atherogenic and atheroprotective mech-anisms. Nat. Rev. Cardiol., 2011, 8, 222-232.
138. Kontush, A.; Chapman, M. J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol., 2010, 21, 312-318.
139. Vaziri, N. D.; Moradi, H.; Pahl, M. V.; Fogelman, A. M.; Navab, M. In vitro stimulation of HDL anti-inflammatory activity and in-hibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int., 2009, 76, 437-444.
140. Gruber, J. H.; Bernecker, C.; Pailer, S.; Lechner, A.; Horejsi, R.; Möller, R.; Fazekas, F.; Truschnig-Wilders, M. Lipid profile in normal weight migraineurs-evidence for cardiovascular risk. Eur. J. Neurol., 2010, 17, 419-442.
141. Schürks, M.; Buring, J. E.; Kurth, T. Migraine, migraine features, and cardiovascular disease. Headache, 2010, 50, 1031-1040.
142. ] Erel, O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem., 2005, 38, 1103-1111.
143. Erel, O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS rad-ical cation. Clin. Biochem., 2004, 37, 277-85.
144. Eckerson, H. W.; Wyte, M. C.; La Du, B. N. The human serum araoxonase/arylesterase polymorphism. Am. J. Hum. Genet., 1983, 35, 1126-1138.
145. Haagen, L.; Brock, A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hy-drolisis of 4-nitrophenyl acetate. Eur. J. Clin. Chem. Clin. Bio-chem., 1992, 30, 391-395.